Treatment of HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis: Toward Rational Targeted Therapy. Export

@article{citeulike:3078467, abstract = {The treatment of HAM/TSP is a challenge. No agent has shown to significantly modify the long-term disability associated with HAM/TSP. Advances in our understanding of the pathogenesis of HAM/TSP have led to the identification of several biomarkers and therapeutic targets. Clinical trials in HAM/TSP continue to be opportunities for further qualification and refinement of biomarkers and therapeutic targets. The validation of HAM/TSP relevant biomarkers and the identification of new targets remain key challenges in the development of effective targeted therapy in HAM/TSP.}, address = {Viral Immunology Section, Neuroimmunology Branch, National Institute of Neurological Diseases and Stroke, 10 Center Drive, Bldg 10 Rm 5C103, Bethesda, MD 20892, USA.}, author = {Oh, U. and Jacobson, S.}, citeulike-article-id = {3078467}, citeulike-linkout-0 = {http://dx.doi.org/10.1016/j.ncl.2008.03.008}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/18657726}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=18657726}, doi = {10.1016/j.ncl.2008.03.008}, issn = {0733-8619}, journal = {Neurologic clinics}, keywords = {hamtsp, hamtsp\_therapy, review, translational\_hamtsp}, month = {August}, number = {3}, pages = {781--797}, posted-at = {2008-08-03 14:26:35}, priority = {2}, title = {Treatment of HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis: Toward Rational Targeted Therapy.}, url = {http://dx.doi.org/10.1016/j.ncl.2008.03.008}, volume = {26}, year = {2008} }

TY - JOUR ID - citeulike:3078467 L3 - citeulike-article-id:3078467 N2 - The treatment of HAM/TSP is a challenge. No agent has shown to significantly modify the long-term disability associated with HAM/TSP. Advances in our understanding of the pathogenesis of HAM/TSP have led to the identification of several biomarkers and therapeutic targets. Clinical trials in HAM/TSP continue to be opportunities for further qualification and refinement of biomarkers and therapeutic targets. The validation of HAM/TSP relevant biomarkers and the identification of new targets remain key challenges in the development of effective targeted therapy in HAM/TSP. IS - 3 JF - Neurologic clinics SN - 0733-8619 AD - Viral Immunology Section, Neuroimmunology Branch, National Institute of Neurological Diseases and Stroke, 10 Center Drive, Bldg 10 Rm 5C103, Bethesda, MD 20892, USA. EP - 797 TI - Treatment of HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis: Toward Rational Targeted Therapy. VL - 26 SP - 781 KW - hamtsp KW - hamtsp_therapy KW - review KW - translational_hamtsp AU - Oh, U AU - Jacobson, S PY - 2008/08// UR - http://dx.doi.org/10.1016/j.ncl.2008.03.008 ER -